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A Reduced Sensitivity for Activated Protein C in the Absence of Factor V Leiden
Increases the Risk of Venous Thrombosis
By Maneke C H de Visser, Frits R. Rosendaal, and Rogier M Bertina
Activated protem C (APC) resistance caused by the factor V
Leiden mutation is associated with an mcreased risk of
venous thrombosis. We investigated whether a reduced
response to APC, not due to the factor V pomt mutation, is
also a risk factor for venous thrombosis. For this analysis, we
used the Leiden Thrombophilia Study (LETS), a case-control
study for venous thrombosis mcludmg 474 patients with a
first deep-vem thrombosis and 474 age- and sex-matched
controls. All carners of the factor V Leiden mutation were
excluded. A dose-response relationship was observed be-
tween the sensitivity for APC and the risk of thrombosis: the
Iower the normalized APC sensitivity ratio, the higher the
associated risk. The risk for the Iowest quartile of normalized
APC-SR (<0.92), which mcluded 16.5% of the healthy
controls, compared with the highest quartile (normalized
APC-SR > 1 05) was greater than fourfold mcreased (OR =
4.4; 95% confidence mterval, 2.9 to 6 6). We adjusted for
VIII'C levels, which appeared to affect our APC resistance
test. The adjusted (age, sex, FVIII C) odds ratio for the Iowest
quartile was 2.5 (95% confidence mterval, 1.5 to 4.2). So,
after adjustment for factor VIII levels, a reduced response to
APC remamed a risk factor. Our results show that a reduced
sensitivity for APC, not caused by the factor V Leiden
mutation, is a risk factor for venous thrombosis.
© 1999 by The American Society of Hematology.
A KEY COMPONENT m the anücoagulant pathway isprotem C, the zymogen of a Vitamin K-dependent senne
protease Protein C is acüvated on endothehal cells by thrombin
bound to thrombomoduhn Activated protem C (APC) exerts its
anticoagulant function by proteolytic cleavage of the procoagu
lant protems factor Va and factor Villa Protem S functions äs a
cofactor m this reaction (for a review, see Esmon and Schwarz1)
The phenomenon of resistance to APC was first reported by
Dahlback et al in 1993 2 It is defined äs a poor anticoagulant
response of plasma to APC and is associated with an mcreased
risk of thrombosis 3 4 In 1994 it was found that APC resistance is
almost always associated with the presence of a mutation in one
of the APC cleavage sites (Arg 506) of factor V, resulting in a
mutant factor V (factor V Leiden)5 The acüvated factor V
vanant is more slowly mactivated by APC than acüvated
wild type factor V69 APC resistance caused by the factor V
Leiden mutation is a common and strong risk factor for venous
thrombosis, with a threefold to sevenfold mcreased risk for
heterozygous mdividuals and an 80 fold mcreased risk for
homozygous mdividuals 10 u
Most cases of APC resistance can be explamed by the factor
V Leiden mutation However, there are subjects who appear
APC resistant äs defined by arbitrary cutoff pomts in functional
tests but who do not carry the factor V Leiden mutation Certam
acquired conditions, such äs pregnancy12 and oral contraceptive
use,13 may account for a reduced response to APC Patients with
acute thromboüc events have also been found to have acquired
APC resistance,14 which may be due to the associated acute-
phase reaction A non-factor V Leiden-related APC resistance
was also reported in patients with stroke,1116 but it is unknown
if this is caused by genetic or acquired conditions Some
laboratory phenotypes, such äs lupus anticoagulant17 and high
factor VIII levels,1819 are also associated with a reduced
sensitivity for APC The detection of an APC resistant pheno
type depends on the type of clottmg test and on the particular
reagent that is used It is not known if this acquired APC
resistance is associated with an mcreased risk of thrombosis
In some patients, the APC resistant phenotype without the
factor V mutation might be related to acquired conditions, m
others, there is no obvious reason In family studies and in
case-control studies it has been observed that thrombotic
mdividuals without the factor V Leiden mutation have Iower
APC ratios than nonthrombotic subjects2021 These observa
üons suggest that a reduced response to APC may be a risk
factor per se for venous thrombosis and that the APC sensitivity
ratio might constitute a useful climcal variable
We have investigated whether a reduced sensitivity for APC,
not due to factor V Leiden, is a risk factor for venous
thrombosis We also looked at the mfluence of certain variables
(factor Vin, factor II, factor X, protem C, protem S [total and
free], and fibnnogen levels and oral contraceptive use) on the
APC ratio äs measured by our local test For our mvestigation
we used a population-based case control study on venous
thrombosis (The Leiden Thrombophilia Study [LETS])
PATIENTS AND METHODS
Subjects The design of oui population-based case conüol study
(LETS) has been descnbed previously1 Bnefly, consecutive patients
with a first episode of deep vem thrombosis were selected fiom the files
of three anticoagulaüon chmcs m The Netheilands These chmcs
momtor the anticoagulant tieatment of virtually all patients withm a
well defined geographical area All patients were younger than 70 years
of age and were not diagnosed wrth mahgnant disoiders Controls were
acquamtances of patients or paitners of other patients matched for age
and sex with the cases The study mcluded 474 patients and 474
controls
For the present mvestigation, all subjects with the factor V Leiden
mutation (heterozygous and homozygous) were excluded (n = 106)
Patients usmg oral anticoagulants (n = 48) or with a lupus anticoagulant
(n = 4) were also excluded, because they have a piolonged activated
partial thromboplastm time (APTT) in the absence of APC leadmg to
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unrehable results in the APC resistance test After this selection, 337
patients and 455 controls were left for our analysis
Blood collection and laboratory analysis Blood was collected into
tubes contaming 0 106 mmol/L tnsodium citrate Plasma was prepared
by centnfugaüon for 10 mmutes at 2,000g at room temperature and
stored at -70°C High molecular weight DNA was isolated from
leukocytes and stored at 4°C The presence of the factor V Leiden
mutation was determined äs previously descnbed5
The sensitivity of the plasma APTT to APC was measured äs
descnbed before ^ Bnefly, 50 μι undiluted plasma was mcubated with
50 μΐ^ APTT reagent (Cephotest, Nycomed Pharma, Oslo, Norway) for
6 mmutes at 37°C For measurmg the APTT m the absence of APC, clot
formation was started with 50 μι of 33 mmol/L calcmm chlonde, 25
mmol/L Tns HC1 (pH 7 5), 50 mmol/L sodium chlonde, and 0 05%
ovalbumm (solution A) The APTT m the presence of APC was
measured by addmg 50 μL of solution A also contaming 2 0 μg/mL
human APC and 0 6% glycerol Automated analysis was performed on
an ACL-300 (Instrumentation Laboratory, Milan, Italy) To reduce
between-assay Variation, results are expressed äs normahzed APC
sensitivity ratios (n APC-SR) The APC sensitivity ratio (APC-SR) is
defined äs the APTT in the presence of APC divided by the APTT in the
absence of APC The normahzed APC-SR is calculated by dividing the
APC-SR of the patient by the APC SR of pooled normal plasma that is
measured m the same run APC was prepared from isolated human
protein C äs previously descnbed22 and stored in small amounts at
-30°C m a buffer contaming 50 mmol/L Tris-HCl (pH 75), 100
mmol/L sodium chlonde, 01% ovalbumm, and 7 5% glycerol
Protein C activity was measured with Coamate (Chromogemx,
Molndal, Sweden) on an ACL-200 (Instrumentation Laboratory), factor
II activity was measured with a chromogenic method usmg S-2238
(Chromogemx) and Echis Cannatus snake venom (Sigma Chemical
Co, St Louis, MO)23 on an ACL 200, and factor X antigen was
measured by enzyme hnked immunosorbent assay (ELISA) with a
polyclonal antibody (DAKO, Glostrup, Denmark) Total protein S was
measured by polyclonal ELISA24 and free protein S was measured
directly m plasma by ELISA usmg two monoclonal antibodies specific
for fiee protein S (Asserachrom free protein S, Diagnostica Stago,
Asmeies-sur-Seme, France)25 26 The fibnnogen concentration was
determined according to method of Clauss usmg Dade thrombin reagent
(Baxter, Miami, FL) on an Electra 1000 (MLA, Pleasantville, NY)
Factor VIII coagulant activity was measured by a one stage clottmg
assay with FVIII-deficient plasma and automated APTT (Organon
Teknica, Durham, NC) on an Electra 1000 Factor VIII C was expressed
m units per decihter One umt corresponds with 0 93 international units
(IU) The results of all these measurements, except those for factor X,
have been reported previously ^27 29
The techmcians were at all times unaware of the Status of the sample
(le, patient or control)
Statisttcal analysis Odds ratios (ORs) weie calculated äs estimates
of the relative nsk of thrombosis in the Standard unmatched fashion
Ninety-five percent confidence intervals (95% CI) were constructed
according to Woolf TO We adjusted for the matchmg variables age and
sex äs well äs for putative confounders by unconditional logistic
regression Factor VIII, factor II, factor X, protein C, protein S (total and
free), and fibrmogen levels were entered into the logistic model äs
categonzed variables (approximate tertiles)
RESULTS
The ratio of male to female subjects was l l 5 for the patients
and l l 3 for the controls The mean age was 47 years for both
groups (ränge, 16 to 70 years for the patients and 16 to 73 years
for the controls) The median time between the occurrence of
deep-vem thrombosis and venepuncture for this study was 18
months (ränge, 6 to 55 months)
The mean n-APC-SR was 0 96 (ränge, 0 76 to l 35) for the
patients and l 02 (ränge, 0 74 to l 50) for the controls The
mean normahzed APC-SR was higher m men than m women for
patients and controls Among the controls, the mean normahzed
APC-SR for men was l 06 (ränge, 0 82 to l 41) and for women
l 00 (ränge, 0 74 to l 50) Among the patients, the mean
normahzed APC-SR for men was 0 99 (ränge, 0 80 to l 26) and
for women 0 94 (ränge, 0 67 to l 35) The mean normahzed
APC-SR for women not usmg oral contraceptives at the time of
venepuncture was slightly higher than that for the whole group
of women, le, l 04 (ränge, 0 78 to l 50) for women controls and
0 97 (ränge, 0 67 to l 35) for women patients The normahzed






Fig 1. Normalized APC sensi-
tivity ratios m 337 patients with
deep-vem thrombosis and 455
controls None of these subjects
carries the factor V Leiden muta-
tion. The horizontal Imes reprc-
sent the median n-APC-SR (0 95
for patients and 1.01 for con-
trols), the 95th porcontile (P95;
1.14 for patients and 1 24 for
controls), and the 10th percen-
tile (ΡΊΟ; Ο 83 for patients and
0.89 for controls)




Fig 2. Odds ratio for venous
thrombosis, accordmg to normal-
ized APC sensitivity ratio. ORs
are adjusted for age and sex. The
reference category was formed
by the subjects with an n-APC-SR
greater than 1.18 (OR, 1; mdi-
cated with an astensk). The 95%
Cl are represented by error bars.
We stratified the patients and the controls mto 10 groups
accordmg to the normahzed APC-SRs of the controls and
calculated, äs a measure of the relative nsk, the odds ratios
(ORs) for thrombosis for the patients with lower normahzed
APC-SRs äs compared with those with the highest normahzed
APC-SRs (> l 18,Fig2) The lOth percentile of the normahzed
APC-SRs for controls was 0 89 Of the 337 patients, 79 (23 4%)
had a normahzed APC-SR below this cutoff, compared with 37
(8 1%) of the healthy controls The 90th percentile of the
normahzed APC SRs for controls was l 18 Eleven cases
(3 3%) and 48 controls (105%) had a normahzed APC-SR
above this cutoff So, the crude OR for venous thrombosis for
subjects with a normahzed APC-SR below the lOth percentile
was 9 3 (95% CI, 4 4 to 20) äs compared with those with a
normahzed APC-SR above l 18 (90th percentile) The adjusted
(sex and age) OR (Fig 2) for this group was even higher,
indicating an 11-fold increased nsk compared with the group
with the highest normahzed APC-SR (OR, 11 2, 95% CI, 5 l to
24 6) Figure 2 shows that the OR for venous thrombosis
steadily increases when the normahzed APC-SR decreases
Table l shows the OR after stratification of the normahzed
Table 1. Thrombosis Risk for Normahzed APC Sensitivity




Men (n = 333)
Women (n = 459)
n APC SR
>1 05
0 99 1 05
0 92 0 98
<092
>1 10


















































1 5 3 4
2 9 6 6
0 9 3 4
1 349
24-92
0 9 2 5
1 340
3 0 9 4
Normalized APC sensitivity ratio
APC-SRs of patients and controls mto quartiles The ORs are
relative to the reference category (OR, 1), and show for both
sexes together an increased nsk associated with a poorer
response to APC Subjects with a normahzed APC SR below
0 92 had a 4 4-fold higher risk than those m the reference
category (n-APC-SR > l 05) Because women appeared to have
a lower average normahzed APC-SR than men, we also
performed the stratification and calculation of the ORs for men
and women separately (le, with sex-specific quartile cut-off
values) For both sexes similar results were obtamed with a
fourfold to fivefold increased nsk m the lowest quartile
Because APC sensitivity, äs measured with our lest, may be
mfluenced by other variables (eg, factor VIII levels), we
assessed whether the effects of these other variables might
explam the observed association, le, whether the association
was confounded Adjustment for protein C, protein S (free or
total), factor X, factor II, or fibnnogen levels or for oral
contraceptive use at the time of venepuncture did not change the
reported OR for the lowest quartile (Table 2) To act äs a
confounder, a variable has to be associated to the putaüve risk
factor and be a risk factor itself As we showed previously, high
factor Vin C levels mcrease the risk of thrombosis,27 and, äs is
Table 2. Adjusted ORs for n-APC-SR Less Than 0.92




Age, sex, oral contraceptive use
Age, sex, factor II
Age, sex, factor X
Age, sex, protein S free
Age, sex, protein S total
Age sex, protein C
Age, sex, fibnnogen













2 9 6 6
3 1 7 3
3 7 9 3
2 6 6 5
3 3 8 1
30-72
2 9 7 0




Factor II, factor X, protein S free, protein S total, protein C,
fibnnogen, and factor VIII C were entered mto the logistic model äs
categonzed variables (approximatetertiles)
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shown m Fig 3, factor VIII C levels and normahzed APC-SR
are mdeed correlated (regression coefficient β = - 002) When
we adjusted for factor VIII C levels by logistic regression, the
OR decreased This confoundmg was only partial, because the
risk associated with normahzed APC-SR remained clearly
elevated after adjustment for factor VIII C (Table 3) Entering
of factor Vin C mto the logistic model äs a contmuous variable
gave similar results äs entering it äs a categonzed variable Of
all 197 subjects with an APC response in the lowest quartile
(<0 92), 45% (28 controls and 60 patients) had a high factor
VIII C level (>150 TU/dL, äs defined by Koster et al27) The
adjusted (sex, age, and FVIII C) OR for the group below the
lOth percentile (n-APC-SR <0 89) compared with the group
above the 90th percentile (n-APC-SR >1 18) was 5 4 (95% CI,
2 3 to 12 8)
DISCUSSION
APC resistance caused by the factor V Leiden mutation is a
strong risk factor for venous thrombosis m n Our study shows
that a reduced sensitivity for APC m the absence of the factor V
Leiden mutation is also associated with an increased risk of
venous thrombosis This association appeared to have a dose-
response relationship, le, the lower the normahzed APC sensitiv-
ity ratio, the higher the risk As our results show, this reduced
sensitivity for APC is a common risk factor for thrombosis the
risk adjusted for factor VIII in the lowest quartile, le, with a
sensitivity that has a prevalence of 25%, was 2 5-fold increased
The lower response of patients compared with controls may
reflect a postthrombotic effect, but the median time between
thrombotic event and venepuncture for our study was 18
months, which makes this explanation unhkely
It has been demonstrated previously that a commercial APC
resistance lest (Chromogemx) is sensitive for factor VIII
levels 1819 We showed that high factor VIII levels also mfluence
Table 3. Odds Ratlos Adjusted for Sex, Age, and Factor VIII.C Levels
n APC SR
>1 05
0 99 1 05








0 8 2 0
0 9 2 3
1 542
*Reference category
our local APC resistance lest After stratification of the normal-
ized APC-SRs mto quartiles, we observed that 45% of the
subjects m the lowest quartile (n-APC-SR <0 92) had high
factor Vin C levels (>150 lU/dL) High levels of factor VIII
are a risk factor for venous thrombosis 27 After correction for
the confoundmg effect of factor VIII levels, a low response to
APC remained, although attenuated, a marked risk factor for
venous thrombosis Other variables (factor II, factor X, fibrmo-
gen, protein S [free and total], and protein C concentrations) did
not mfluence the reported odds ratlos The estabhshed increased
risk was also not confounded by oral contraceptive use, another
risk factor for venous thrombosis Even though oral contracep-
tive users have lower normahzed APC-SRs than nonusers,
thrombosis patients usmg oral contraceptives still have lower
ratlos than controls usmg oral contraceptives 31
The APTT-based APC resistance lest detects states with low
or high sensitivity for the degradation of factor Va and Villa by
APC Factor V Leiden is known to be responsible for most cases
of low sensitivity for APC After the discovery of the factor V
Leiden mutation, the APC resistance lest has been widely used
äs a screening assay for this pomt mutation, whereby an
arbitrarily chosen cutoff pomt is used to identify subjects to be
APC resistant Modified tests (eg, dilution in factor V-deficient
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FactorVIII:C(u/dL)
Fig 3. Factor VIII C level and
normahzed APC sensitivity ratio
in patients (A) and controls (D)
Regression coefficient β = -.002.
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for the factor V Leiden mutation An advantage of these tests is
that they can also be used for the detecüon of the factor V
mutation in patients usmg oral anticoagulants or m patients with
lupus anticoagulants A disadvantage of these tests is that they
cannot detect a reduced sensitivity for APC m the absence of
factor V Leiden, which, äs we have shown here, is a nsk factor
for venous thrombosis By measurmg the APC response with
the original test, valuable Information is obtamed concerning
the protein C/protem S System across all levels, because, apart
from the factor V Leiden mutation, other factors (eg, factor VIII
level) determme the APC response
It was demonstrated previously that our local APC resistance
test, with Cephotest äs activator, has a high sensitivity and
specificity for the factor V Leiden mutation 5 32 31 Homozygotes
for the factor V Leiden mutation have a normalized APC-SR of
less than 0 45, heterozygotes have a normalized APC-SR
of 0 45 to 0 70, and noncarriers have a normalized APC-SR of
^0 70 So, there is no overlap in APC ratios between factor V
Leiden carriers and noncarriers Of our study population of
noncarriers, only l patient had an aberrant ratio (n-APC-SR =
0 67) according to this distnbution
States with a low sensitivity for APC not caused by factor V
Leiden may correspond to acquired conditions, äs is reported
for pregnancy,12 oral contraceptive use,13 and lupus anticoagu-
lant n It may also be due to other mherited traits Apart from the
factor V Leiden mutation, no other common genetic causes for
APC resistance have been found to date Bernardi et al34
reported that the HR2 haplotype is associated with significantly
lower APC ratios m patients and in controls Recently, two
mutations involving the Arg306 APC cleavage site of factor V
were descnbed3S 36 One mutation (Arg 306 Thr, factor V
Cambridge), which was found in l patient and in a first degree
relative, was indeed associated with APC resistance The other
mutation (Arg 306 Gly), found in Hong Kong Chinese, was
reported to be not associated with APC resistance Zoller et al21
descnbed in 1994 three famihes with APC resistance without
the factor V Leiden mutation No explanation for the APC
resistance phenotype in these three famihes has been reported
yet No mutations have been found in APC cleavage sites in
factor Vin 37 38 Recently, Amano et al39 demonstrated with
FVIII mutants that only a double mutant FVIII, with APC
cleavage sites Arg336 and Arg562 affected, resulted m an
APC-resistant phenotype
It is tempting to compare the nsks observed in this study with
the nsk for factor V Leiden carriers Previously, we reported an
eightfold increased nsk (calculated from Rosendaal et al10) for
carriers of factor V Leiden versus noncarriers This nsk cannot
be compared with the risk in the present study, because the
reference group is different (all noncarriers of factor V Leiden v
noncarriers with high APC sensitivity ratios m this study)
When we include factor V Leiden carriers in whom the
normalized APC-SR was measured (81 patients and 14 con-
trols), their risk compared with the reference group of noncarri-
ers with a normalized APC-SR greater than l 18 (11 patients
and 48 controls, see Results) was 25 2 (95% CI, 10 6 to 60 1)
This indicates that m carriers of factor V Leiden the nsk is
about threefold higher than in thos>e with normal factor V and a
low APC sensitivity ratio The factor V Leiden carriers also had
the lowest normalized APC-SRs, which was invanably less than
0 70, whereas only l noncamer with a normalized APC-SR less
than 0 89 had a ratio less than 0 70 So, another way of assessmg
these data is calculatmg the risk of normalized APC SR less
than 0 70 (95 factor V Leiden carriers, l noncamer, 82 patients,
and 14 controls) to those with a normalized APC-SR greater
than l 18 In this companson, the OR becomes 25 6 (95% CI,
10 7 to 60 8), agam showing that the lower the ratio, the higher
the risk
We conclude that a reduced response to APC, äs measured by
our local test, increases the risk of venous thrombosis Because
of the clear dose-response relationship between the normalized
APC sensitivity ratio and the risk of venous thrombosis, it is
difficult to assign a cutoff point that determmes subjects to have
this type of APC resistance It must be emphasized that the nsk
for the APC resistance in factor V Leiden carriers is higher than
the risk for noncarriers with a reduced normalized APC-SR
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